Associated Papers
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
38802404 (PubMed )
Supplement: 41397_2024_338_MOESM2_ESM.xlsx › Sheet1
Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub-Saharan African Populations.
Twesigomwe D et al.
Clinical Pharmacology and Therapeutics, 2024
Transferability of Ancestry-Specific and Cross-Ancestry CYP2A6 Activity Genetic Risk Scores in African and European Populations.
El-Boraie A et al.
Clinical Pharmacology and Therapeutics, 2021
Pharmacogene Sequencing of a Gabonese Population with Severe Plasmodium falciparum Malaria Reveals Multiple Novel Variants with Putative Relevance for Antimalarial Treatment.
Pernaute-Lau L et al.
Antimicrobial Agents and Chemotherapy, 2021
Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities.
Hosono H et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2017
Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction.
López-Flores LA et al.
Excli Journal, 2017
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent.
Mwenifumbo JC et al.
Human Mutation, 2008
Three haplotypes associated with CYP2A6 phenotypes in Caucasians.
Haberl M et al.
Pharmacogenetics and Genomics, 2005
Select a paper to view details